Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome

Journal of Bone and Mineral Research

Volumn 31, Issue 10, 2016, Pages 1845-1854

  Ramnitz, Mary Scott ^a   Gourh, Pravitt ^b   Goldbach Mansky, Raphaela ^b   Wodajo, Felasfa ^c   Ichikawa, Shoji ^d   Econs, Michael J ^d   White, Kenneth E ^d   Molinolo, Alfredo ^a   Chen, Marcus Y ^e   Heller, Theo ^f   Del Rivero, Jaydira ^g   Seo Mayer, Patricia ^h   Arabshahi, Bita ⁱ   Jackson, Malaka B ^j   Hatab, Sarah ^k   McCarthy, Edward ^l   Guthrie, Lori C ^a   Brillante, Beth A ^a   Gafni, Rachel I ^a   Collins, Michael T ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^c Musculoskeletal Tumor Surgery   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Virginia Cancer Specialists   (United States)

^j UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^k EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l JOHNS HOPKINS HOSPITAL   (United States)

more..

Author keywords

FAMILIAL TUMORAL CALCINOSIS; FIBROBLAST GROWTH FACTOR 23; HYPEROSTOSIS HYPERPHOSPHATEMIA SYNDROME; HYPERPHOSPHATEMIA

Indexed keywords

C REACTIVE PROTEIN; CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; N ACETYLGALACTOSAMINYLTRANSFERASE; BETA GLUCURONIDASE; FIBROBLAST GROWTH FACTOR; KLOTHO PROTEIN; POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE;

ADOLESCENT; ADULT; ARTICLE; BONE DENSITY; CHEMILUMINESCENCE IMMUNOASSAY; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; HYPEROSTOSIS; HYPERPHOSPHATEMIA; IMMUNE RESPONSE; INFLAMMATION; LIQUID CHROMATOGRAPHY; MALE; MIDDLE AGED; MORPHOLOGICAL TRAIT; PHOSPHATE METABOLISM; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE; SCHOOL CHILD; TANDEM MASS SPECTROMETRY; TUMOR CALCINOSIS; BLOOD; CAFFEY DISEASE; CALCINOSIS; CLINICAL TRIAL; COHORT ANALYSIS; GENETICS; PATHOLOGY;

ADOLESCENT; ADULT; CALCINOSIS; CHILD; COHORT STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; HYPEROSTOSIS; HYPEROSTOSIS, CORTICAL, CONGENITAL; HYPERPHOSPHATEMIA; MALE; N-ACETYLGALACTOSAMINYLTRANSFERASES;

EID: 84988385354     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2870     Document Type: Article

References (38)

1. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet. 2005 Feb 1; 14(3):385–90.
2. Topaz O, Shurman DL, Bergman R, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet. 2004 Jun; 36(6):579–81.
3. Ichikawa S, Imel EA, Kreiter ML, et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Musculoskelet Neuronal Interact. 2007 Oct-Dec; 7(4):318–9.
4. Bhattacharyya N, Chong WH, Gafni RI, Collins MT. Fibroblast growth factor 23: state of the field and future directions. Trends Endocrinol Metab. 2012 Dec; 23(12):610–8.
5. Kato K, Jeanneau C, Tarp MA, et al. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem. 2006 Jul 7; 281(27):18370–7.
6. Narchi H. Hyperostosis with hyperphosphatemia: evidence of familial occurrence and association with tumoral calcinosis. Pediatrics. 1997 May; 99(5):745–8.
7. Dumitrescu CE, Kelly MH, Khosravi A, et al. A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features. Osteoporos Int. 2009 Jul; 20(7):1273–8.
8. Burkes EJ Jr, Lyles KW, Dolan EA, Giammara B, Hanker J. Dental lesions in tumoral calcinosis. J Oral Pathol Med. 1991 May; 20(5):222–7.
9. Gal G, Metzker A, Garlick J, Gold Y, Calderon S. Head and neck manifestations of tumoral calcinosis. Oral Surg Oral Med Oral Pathol. 1994 Feb; 77(2):158–66.
10. Krstevska A, Gale S, Blair F. Tumoral calcinosis: a dental literature review and case report. Dent Update. 2012 Jul-Aug; 39(6):416–8, 21.
11. Yamaguchi T, Sugimoto T, Imai Y, Fukase M, Fujita T, Chihara K. Successful treatment of hyperphosphatemic tumoral calcinosis with long-term acetazolamide. Bone. 1995 Apr; 16(4 Suppl):247S–50S.
12. Lammoglia JJ, Mericq V. Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer. Horm Res. 2009; 71(3):178–84.
13. Alkhooly AZ. Medical treatment for tumoral calcinosis with eight years of follow-up: a report of four cases. J Orthop Surg. 2009 Dec; 17(3):379–82.
14. Ichikawa S, Baujat G, Seyahi A, et al. Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. Am J Med Genet A. 2010 Apr; 152A(4):896–903.
15. Lafferty FW, Reynolds ES, Pearson OH. Tumoral calcinosis: a metabolic disease of obscure etiology. Am J Med. 1965 Jan; 38:105–18.
16. Yancovitch A, Hershkovitz D, Indelman M, et al. Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis. J Bone Miner Metab. 2011 Sep; 29(5):621–5.
17. Zemel BS, Kalkwarf HJ, Gilsanz V, et al. Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study. J Clin Endocrinol Metab. 2011 Oct; 96(10):3160–9.
18. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990 Mar 15; 15(4):827–32.
19. Alon U, Hellerstein S. Assessment and interpretation of the tubular threshold for phosphate in infants and children. Pediatr Nephrol. 1994 Apr; 8(2):250–1.
20. Langman CB, Salusky IB. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Children with Chronic Kidney Disease - Foreword. Am J Kidney Dis. 2005 Oct; 46(4):S6–S121.
21. Bhattacharyya N, Wiench M, Dumitrescu C, et al. Mechanism of FGF23 processing in fibrous dysplasia. J Bone Miner Res. 2012 May; 27(5):1132–41.
22. Goetz R, Nakada Y, Hu MC, et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A. 2010 Jan 5; 107(1):407–12.
23. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011 Jun; 18(3):R53–77.
24. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003 Apr 24; 348(17):1656–63.
25. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 2001 Dec; 60(6):2079–86.
26. Chefetz I, Heller R, Galli-Tsinopoulou A, et al. A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification. Hum Genet. 2005 Nov; 118(2):261–6.
27. Shah A, Miller CJ, Nast CC, et al. Severe vascular calcification and tumoral calcinosis in a family with hyperphosphatemia: a fibroblast growth factor 23 mutation identified by exome sequencing. Nephrol Dial Transplant. 2014 Dec; 29(12):2235–43.
28. Mahdavi H, Kuizon BD, Gales B, Wang HJ, Elashoff RM, Salusky IB. Sevelamer hydrochloride: an effective phosphate binder in dialyzed children. Pediatr Nephrol. 2003 Dec; 18(12):1260–4.
29. Lufkin EG, Wilson DM, Smith LH, et al. Phosphorus excretion in tumoral calcinosis: response to parathyroid hormone and acetazolamide. J Clin Endocrinol Metab. 1980 Apr; 50(4):648–53.
30. Leibrock CB, Alesutan I, Voelkl J, et al. Acetazolamide sensitive tissue calcification and aging of klotho-hypomorphic mice. J Mol Med. 2015 Aug 27.
31. Garringer HJ, Fisher C, Larsson TE, et al. The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis. J Clin Endocrinol Metab. 2006 Oct; 91(10):4037–42.
32. Finer G, Price HE, Shore RM, White KE, Langman CB. Hyperphosphatemic familial tumoral calcinosis: response to acetazolamide and postulated mechanisms. Am J Med Genet A. 2014 Jun; 164A(6):1545–9.
33. Nakamura H, Kawakami A, Ida H, Ejima E, Origuchi T, Eguchi K. Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis. J Rheumatol. 2006 Aug; 33(8):1691–3.
34. Masi L, Beltrami G, Ottanelli S, et al. Human preosteoblastic cell culture from a patient with severe tumoral calcinosis-hyperphosphatemia due to a new GALNT3 gene mutation: study of in vitro mineralization. Calcif Tissue Int. 2015 May; 96(5):438–52.
35. Slavin RE, Wen J, Barmada A. Tumoral calcinosis—a pathogenetic overview: a histological and ultrastructural study with a report of two new cases, one in infancy. Int J Surg Pathol. 2012 Oct; 20(5):462–73.
36. Slavin RE, Wen J, Kumar D, Evans EB. Familial tumoral calcinosis. A clinical, histopathologic, and ultrastructural study with an analysis of its calcifying process and pathogenesis. Am J Surg Pathol. 1993 Aug; 17(8):788–802.
37. Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr Endocrinol Rev. 2013 Jun;10 Suppl 2:437–48.
38. Foster BL, Ramnitz MS, Gafni RI, et al. Rare bone diseases and their dental, oral, and craniofacial manifestations. J Dent Res. 2014 Jul; 93(7 Suppl):7S–19S.